CRISPR Therapeutics AG — Director's Dealing 2017

Jun 2, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2017-05-31

Reporting Person: Behbahani Ali (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-05-31	Stock Option (Right to Buy)	$13.62	A	15000	Acquired	2027-05-31	Common Shares (15000)	Direct

Footnotes

F1: This option was granted on May 31, 2017 with respect to 15,000 Common Shares with the shares vesting in 12 equal monthly installments.